MX2023010442A - Antagonistas de actrii-alk4 y métodos para el tratamiento contra la insuficiencia cardíaca. - Google Patents
Antagonistas de actrii-alk4 y métodos para el tratamiento contra la insuficiencia cardíaca.Info
- Publication number
- MX2023010442A MX2023010442A MX2023010442A MX2023010442A MX2023010442A MX 2023010442 A MX2023010442 A MX 2023010442A MX 2023010442 A MX2023010442 A MX 2023010442A MX 2023010442 A MX2023010442 A MX 2023010442A MX 2023010442 A MX2023010442 A MX 2023010442A
- Authority
- MX
- Mexico
- Prior art keywords
- actrii
- alk4
- heart failure
- antagonists
- methods
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title abstract 6
- 239000005557 antagonist Substances 0.000 title abstract 4
- 230000032683 aging Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163159059P | 2021-03-10 | 2021-03-10 | |
| PCT/US2022/019557 WO2022192404A1 (en) | 2021-03-10 | 2022-03-09 | Actrii-alk4 antagonists and methods of treating heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023010442A true MX2023010442A (es) | 2023-11-22 |
Family
ID=83228300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023010442A MX2023010442A (es) | 2021-03-10 | 2022-03-09 | Antagonistas de actrii-alk4 y métodos para el tratamiento contra la insuficiencia cardíaca. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240197902A1 (https=) |
| EP (1) | EP4304715A4 (https=) |
| JP (1) | JP2024511315A (https=) |
| KR (1) | KR20230169123A (https=) |
| CN (1) | CN117396224A (https=) |
| AU (1) | AU2022235082A1 (https=) |
| BR (1) | BR112023018256A2 (https=) |
| CA (1) | CA3211515A1 (https=) |
| MX (1) | MX2023010442A (https=) |
| WO (1) | WO2022192404A1 (https=) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41920B1 (fr) * | 2015-04-06 | 2021-05-31 | Acceleron Pharma Inc | Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations |
| MA41919A (fr) * | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| DK3496739T3 (da) * | 2016-07-15 | 2021-05-10 | Acceleron Pharma Inc | Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension |
| CA3039573A1 (en) * | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Alk4:actriib heteromultimers and uses thereof |
| GB201620119D0 (en) * | 2016-11-29 | 2017-01-11 | Pharmafox Therapeutics Ag | Compounds |
| JP7669291B2 (ja) * | 2019-05-30 | 2025-04-28 | アクセレロン ファーマ インコーポレーテッド | Ａｃｔｒｉｉ結合性タンパク質及びその使用 |
| US20230174620A1 (en) * | 2020-04-28 | 2023-06-08 | Acceleron Pharma Inc. | Actrii proteins and use in treating post-capillary pulmonary hypertension |
| JP2023534127A (ja) * | 2020-06-17 | 2023-08-08 | アクセルロン ファーマ インコーポレイテッド | ＡｃｔＲＩＩ－ＡＬＫ４アンタゴニストおよび心不全を処置する方法 |
-
2022
- 2022-03-09 JP JP2023554808A patent/JP2024511315A/ja active Pending
- 2022-03-09 AU AU2022235082A patent/AU2022235082A1/en active Pending
- 2022-03-09 BR BR112023018256A patent/BR112023018256A2/pt unknown
- 2022-03-09 KR KR1020237034038A patent/KR20230169123A/ko active Pending
- 2022-03-09 CN CN202280034554.6A patent/CN117396224A/zh active Pending
- 2022-03-09 EP EP22767900.8A patent/EP4304715A4/en active Pending
- 2022-03-09 CA CA3211515A patent/CA3211515A1/en active Pending
- 2022-03-09 MX MX2023010442A patent/MX2023010442A/es unknown
- 2022-03-09 US US18/549,461 patent/US20240197902A1/en active Pending
- 2022-03-09 WO PCT/US2022/019557 patent/WO2022192404A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20240197902A1 (en) | 2024-06-20 |
| WO2022192404A1 (en) | 2022-09-15 |
| CA3211515A1 (en) | 2022-09-15 |
| EP4304715A4 (en) | 2025-01-01 |
| BR112023018256A2 (pt) | 2023-10-31 |
| JP2024511315A (ja) | 2024-03-13 |
| CN117396224A (zh) | 2024-01-12 |
| EP4304715A1 (en) | 2024-01-17 |
| KR20230169123A (ko) | 2023-12-15 |
| AU2022235082A1 (en) | 2023-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022016243A (es) | Antagonistas de actrii-alk4 y métodos para el tratamiento contra insuficiencia cardíaca. | |
| MX2021000276A (es) | Composiciones y metodos para tratar hipertension pulmonar. | |
| EP4616902A3 (en) | Nerve stimulation for treating migraine and other headache conditions | |
| MX2022010425A (es) | Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos. | |
| MX2016016531A (es) | Metodos y composiciones para el tratamiento de las ulceras. | |
| MX362105B (es) | Folistatina en el tratamiento de distrofia muscular de duchenne. | |
| MX2019008124A (es) | Metodos para el tratamiento de trastornos neurologicos. | |
| NZ756936A (en) | Composition and method for preventing or delaying onset of myopia comprising atropine | |
| MX2021004755A (es) | Uso de plasma y fracciones de plasma para mejorar el dolor, la cicatrizacion de heridas y la recuperacion posoperatoria. | |
| MX2023010445A (es) | Antagonistas de actrii-alk4 y metodos para tratar la insuficiencia cardiaca. | |
| WO2020185541A3 (en) | Zilucoplan as deep tissue penetrating c5 inhibitor | |
| MX390722B (es) | Tratamiento de resistencia a diureticos. | |
| WO2022216386A3 (en) | T-type calcium channel antagonists and uses thereof | |
| EP4272829A3 (en) | Peptide having effects of increasing telomerase activity and extending telomere, and composition containing same | |
| MX2023013844A (es) | Metodos para tratar trastornos mieloproliferativos. | |
| MY197654A (en) | Variant dihydrodipicolinate reductase polypeptide and method of producing l-threonine using the same | |
| MX2023010442A (es) | Antagonistas de actrii-alk4 y métodos para el tratamiento contra la insuficiencia cardíaca. | |
| WO2018081401A8 (en) | METHOD FOR INCREASING CELL PROLIFERATION IN BETA PANCREATIC CELLS, PROCESSING METHOD AND COMPOSITION | |
| MX2023004881A (es) | Inhibidores de pde9 para el tratamiento de insuficiencia cardíaca. | |
| WO2019204332A3 (en) | Pak4 inhibitors and methods of use | |
| MX2022007730A (es) | Composiciones de limpieza que comprenden polipeptidos que tienen actividad de alfa amilasa. | |
| WO2022192420A3 (en) | Actrii proteins and uses thereof | |
| MX2021004092A (es) | Contenido reducido de furfural en fibras de celulosa entrelazadas con acido poliacrilico. | |
| EP4246324A3 (en) | Apparatus and method for reducing an energy consumption of hardware based on an application state | |
| ZA202106032B (en) | Communication interface of a secure interface control |